Loading...
Loading...
Jefferies is out with its report today on Cabot
CBT, downgrading CBT from Buy to Hold.
In its report, Jefferies writes, "With near-term demand choppy and Supermetals exiting the portfolio, we are
lowering FY11E EPS $0.25 to $3.20 and FY12E $0.80 to $2.45. Cabot is one of the most intriguing structural transformation stories in chemicals, but near-term
uncertainties likely trump the growth levers. With a better entry point likely in the next 3-6 months, we are lowering our price target $9 to $35 and our rating to Hold."
At the time of posting, shares of CBT were trading at $31.95, down 4.05% from Friday's close.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in